Oligonucleotides Upregulate MECP2 by Blocking PRC2 Repression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Rett syndrome and related disorders, such as MECP2-related severe neonatal encephalopathy and Angelman syndrome, are inadequate due to the inability to effectively upregulate MECP2 protein levels, which are crucial for brain function and synaptic plasticity.
Innovation Solution
Development of single-stranded oligonucleotides that target specific regions of the MECP2 gene to upregulate MECP2 expression by relieving repression mediated by the Polycomb repressive complex 2 (PRC2), using sequences that are complementary to PRC2-associated regions to inhibit PRC2 interaction and enhance MECP2 gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for Rett syndrome, then treatment is available, but MECP2 protein levels cannot be effectively upregulated
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that bind to PRC2-associated regions of MECP2 gene transcripts. These oligonucleotides serve as mediators to block PRC2 interaction with the MECP2 gene, thereby preventing repression and enabling effective upregulation of MECP2 protein levels in Rett syndrome patients.
Solution Approach 2:
The patent changes the molecular interaction parameters by introducing oligonucleotides with specific sequences that complement PRC2-associated regions. This alters the binding dynamics between PRC2 and MECP2, transforming the repressive interaction into a blocked state, which enables reliable MECP2 upregulation to therapeutic levels.
2Stability of the object's composition
If PRC2 interacts with MECP2 gene, then gene repression is maintained, but MECP2 expression is suppressed
Solution Approach 1:
The patent extracts the harmful interaction by using antisense oligonucleotides that specifically bind to PRC2-associated regions on the MECP2 gene transcript. This extraction separates and blocks the PRC2-MECP2 interaction, removing the repressive effect and enabling MECP2 expression to increase to functional levels.
Solution Approach 2:
Instead of attempting to directly activate MECP2 transcription, the patent takes the complementary approach of blocking the repressor (PRC2) from binding to MECP2. By inhibiting the repressive mechanism rather than directly promoting activation, the patent achieves stable MECP2 expression increase.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach significantly increases MECP2 protein levels, providing a potential therapeutic treatment for Rett syndrome and related disorders by modulating gene expression and improving synaptic function.
Implementation Method 1
single stranded oligonucleotides are provided that target a PRC2-associated region of a MECP2 gene... these single stranded oligonucleotides activate or enhance expression of MECP2 by relieving or preventing PRC2 mediated repression of MECP2
Data Source
AI summary
Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of MECP2. Methods for modulating expression of MECP2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2.